Distinguishing active HIV-1 infection from vaccine-induced seropositivity in HIV vaccine trial participants
Science Advances · 2025
DOI: 10.1126/sciadv.adz5639 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Ketan Dighe und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, The Pennsylvania State University, University Park, PA 16802, USA. Hauptthemen laut MEDLINE: AIDS Vaccines, HIV-1, HIV Infections, HIV Seropositivity. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, NIAID NIH HHS, National Institute on Drug Abuse.
Abstract (Originalsprache)
Vaccine-induced seropositivity (VISP) causes antibodies produced by HIV-1 vaccines to react with standard serological tests, complicating diagnosis and leading to false positives. To distinguish VISP from true HIV infections, we developed a rapid, multiplexed companion electrochemical assay that integrates a three-dimensional–printed device with screen-printed electrodes coated with antigen, antibody, and methylene blue–labeled antisense oligonucleotide probes. The test delivers quantitative results within 5 minutes with calculated analytical limits of detection of 5.88 picograms per milliliter for p24 antigen, 10.96 picograms per milliliter for anti-p24 antibody, and 1259 copies per milliliter for HIV-1 RNA, with minimal cross-reactivity. Clinical testing with 104 plasma samples obtained from vaccinated/unvaccinated, HIV-positive/negative individuals demonstrated 95% sensitivity and 98% specificity in distinguishing active HIV-1 infection from VISP cases. Receiver operating characteristic analysis produced area under the curve values of 0.9888 for HIV-1 RNA, 0.9705 for anti-p24 antibody, and 0.9356 for p24 antigen. These findings highlight the potential to reduce false-positive results caused by VISP by integrating this diagnostic test in clinical trials and large-scale vaccination programs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, The Pennsylvania State University, University Park, PA 16802, USA.
- Huck Institutes of Life Sciences, The Pennsylvania State University, University Park, PA 16802, USA.
- Department of Nuclear Engineering, The Pennsylvania State University, University Park, PA 16802, USA.
- Biomedical Engineering Department, Jordan University of Science and Technology, Irbid 22110, Jordan.
- Department of Materials Science and Engineering, The Pennsylvania State University, University Park, PA 16802, USA.
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
ORCID-Profile: Ketan Dighe, Oguzhan Colak, Parikshit Moitra, Maha Alafeef, David Skrodzki, Teresea Aditya, Nivetha Gunaseelan, Casey Pinto, Dipanjan Pan
Förderung
- NIDA NIH HHS
- NIAID NIH HHS
- National Institute on Drug Abuse
- National Institute of Allergy and Infectious Diseases
- Congressionally Directed Medical Research Programs
Zitieren
APA
Dighe, K., Colak, O., Moitra, P., Alafeef, M., Skrodzki, D., Aditya, T., Saha, P., Gunaseelan, N., Hural, J., Pinto, C., & Pan, D. (2025). Distinguishing active HIV-1 infection from vaccine-induced seropositivity in HIV vaccine trial participants. Science Advances. https://doi.org/10.1126/sciadv.adz5639
Vancouver
Dighe K, Colak O, Moitra P, Alafeef M, Skrodzki D, Aditya T, et al. Distinguishing active HIV-1 infection from vaccine-induced seropositivity in HIV vaccine trial participants. Science Advances. 2025. doi:10.1126/sciadv.adz5639
BibTeX
@article{Dighe2025,
author = {Dighe, Ketan and Colak, Oguzhan and Moitra, Parikshit and Alafeef, Maha and Skrodzki, David and Aditya, Teresea and Saha, Pranay and Gunaseelan, Nivetha and Hural, John and Pinto, Casey and Pan, Dipanjan},
title = {Distinguishing active HIV-1 infection from vaccine-induced seropositivity in HIV vaccine trial participants},
journal = {Science Advances},
year = {2025},
doi = {10.1126/sciadv.adz5639}
}
EUVIMED